|Bid||243.13 x 900|
|Ask||245.16 x 800|
|Day's range||242.88 - 246.00|
|52-week range||198.64 - 258.45|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||24.25|
|Forward dividend & yield||7.76 (3.25%)|
|Ex-dividend date||16 May 2022|
|1y target est||N/A|
With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.
In the latest trading session, Amgen (AMGN) closed at $234.72, marking a +1.74% move from the previous day.
Microsoft, Amgen, Honeywell International, Booking Holdings and Stryker have been included in this Analyst Blog.